Text Size

Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study

This study has been completed.
Sponsor:
Information provided by:
Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier:
NCT00986635
First received: September 29, 2009
Last updated: April 7, 2011
Last verified: September 2009
History of Changes
  Purpose

Rivaroxaban represent a new class of anticoagulation agents. As an oral direct factor Xa inhibitor it has been effective in preventing venous thromboembolism in patients undergoing elective orthopaedic surgery. This ex vivo study is undertaken to investigate the ex-vivo effects of Xarelto® on different coagulation parameters.


Condition
Differences in Laboratory Coagulation Parameters

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective

Further study details as provided by Johann Wolfgang Goethe University Hospitals:

Biospecimen Retention:   Samples Without DNA

Plasma samples


Estimated Enrollment: 100
Study Start Date: September 2009
Study Completion Date: April 2011
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Detailed Description:

To validate the effects of Rivaroxaban on coagulation parameters plasma samples of patients after hip or knee replacement surgery treated with Rivaroxaban 10 mg/d are investigated.

Plasma samples are obtained by blood collection before, after 2 hours and after 12 hours after Rivaroxaban dosing in steady state (on 3rd - 5th day).

Several techniques, including clot-based tests, chromogenic assays and ELISA´s are used for coagulation assays in our coagulation laboratory Frankfurt/Main. The influence of Rivaroxaban on different coagulation assays should be investigated in our coagulation laboratory.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients after hip or knee replacement surgery

Criteria

Inclusion Criteria:

  • patients after hip or knee replacement surgery treated with Rivaroxaban 10 mg/d
  • must be able to accept blood sampling
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00986635

Locations
Germany
University Hospital Frankfurt
Frankfurt am Main, Germany, 60590
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospitals
Investigators
Principal Investigator: Helen Mani, PhD Johann Wolfgang Goethe University Hospital Frankfurt/Main Germany
  More Information

No publications provided

Responsible Party: Prof. Dr. Edelgard Lindhoff-Last, MD, Vascular Medicine, Johann Wolfgang Goethe University Hospital Frankfurt/Main
ClinicalTrials.gov Identifier: NCT00986635     History of Changes
Other Study ID Numbers: RIV139/09
Study First Received: September 29, 2009
Last Updated: April 7, 2011
Health Authority: Germany: Ethics Commission

Keywords provided by Johann Wolfgang Goethe University Hospitals:
Activated partial thromboplastin time
Thrombin clotting Time
Anti-Xa-activity
Factor X-activity
 Factor XIII-activity
Antithrombin (based on factor II)
Antithrombin (based on factor X<9

ClinicalTrials.gov processed this record on June 18, 2013